Clinical Report: Via360 Expands Canal-Based MIGS Options

Overview

The Via360 surgical system, cleared by the FDA in February 2025, combines canaloplasty and trabeculotomy, offering surgeons enhanced control over viscoelastic delivery during glaucoma procedures. This device aims to improve intraoperative customization and efficiency in managing intraocular pressure (IOP).

Background

Microinvasive glaucoma surgeries (MIGS) have evolved significantly since the introduction of the first iStent in 2012, with new technologies emerging to improve patient outcomes. The Via360 system represents a notable advancement in canal-based MIGS, allowing for more precise treatment options tailored to individual patient needs, such as improved IOP management and reduced medication burdens. Understanding these innovations is crucial for optimizing glaucoma management.

Data Highlights

No numerical data provided in the source material, but qualitative insights suggest significant advancements in surgical control and patient outcomes.

Key Findings

• The Via360 system integrates canaloplasty and trabeculotomy in a single platform.
• It features ActiveInject technology for on-demand viscoelastic delivery, enhancing surgeon control.
• The microcatheter can advance up to 360° within Schlemm’s canal, allowing for targeted treatment.
• Surgeons can titrate treatment intraoperatively based on patient-specific circumstances.
• The device's design includes microchannels for effective viscoelastic delivery to critical areas, enhancing treatment precision.

Clinical Implications

The Via360 system's unique capabilities may lead to improved IOP management and reduced reliance on glaucoma medications, enhancing patient outcomes and satisfaction through more effective customization of procedures.

Conclusion

The introduction of the Via360 surgical system, cleared by the FDA in February 2025, marks a significant step forward in MIGS technology, providing enhanced control and flexibility for glaucoma specialists. Its innovative design may facilitate more effective treatment strategies tailored to individual patient needs.

Related Resources & Content

1. Ophthalmology Management, 2022 -- THE FUTURE OF MIGS
2. Ophthalmology Management, 2013 -- New Product Report
3. Retinal Physician, 2011 -- Special Section Sponsored By Alcon
4. Glaucoma Physician, 2022 -- Uptake of MIGS Among Glaucoma Specialists Recommendations
5. Primary Open-Angle Glaucoma Preferred Practice Pattern® - PubMed
6. Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System in Patients With Open Angle Glaucoma: A Systematic Review and Meta-analysis - PubMed
7. 15 years of minimally-invasive glaucoma surgeries (MIGS) experience and data: a rationale for optimal clinical decision-making - PMC
8. Primary Open-Angle Glaucoma Preferred Practice Pattern® - PubMed
9. Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System in Patients With Open Angle Glaucoma: A Systematic Review and Meta-analysis - PubMed
10. 15 years of minimally-invasive glaucoma surgeries (MIGS) experience and data: a rationale for optimal clinical decision-making - PMC